Page 165 - MemoriaCIBER2019-ESP

CIBERONC 165
10 publicaciones más relevantes según factor de impacto
FI Publicación 70,67
70,67 59,102
59,102
59,102
44,019 43,704 43,07 43,07 43,07
Grupos CIBERONC. Publicaciones 2019
Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 2019; 381:1535-1546. DOI: 10.1056/NEJMoa1910836.
Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med 2019; 381:2020- 2031. DOI: 10.1056/NEJMoa1910231 (Pubmed ID 31142450).
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive- stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019 Nov 23;394(10212):1929-1939. doi: 10.1016/S0140-6736(19)32222-6. Epub 2019 Oct 4.
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low- dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019 Dec 7;394(10214):2096-2107. doi: 10.1016/S0140-6736(19)32556-5.
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet. 2020 Jan 11;395(10218):132-141. doi: 10.1016/S0140-6736(19)32956-3. Epub 2019 Dec 10.
Dendritic cells in cancer immunology and immunotherapy. Nature Reviews Immunology volume 20, pages7–24(2020).
Clinical epigenetics: seizing opportunities for translation. Nature Reviews Genetics volume 20, pages109–127(2019).
Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy. Nature. 2019 May;569(7756):428-432. doi: 10.1038/s41586-019-1162-y. Epub 2019 May 1.
Recurrent noncoding U1 snRNA mutations drive cryptic splicing in SHH meduloblastoma. Nature volume 574, pages707–711(2019).
The U1 spliceosomal RNA is recurrently mutated in multiple cancers. Nature volume 574, pages712–716(2019).
Jefe de grupo
P Álava Casado, Enrique de
P Albanell Mestres, Joan
P Aranda Aguilar, Enrique
P Arribas López, Joaquín
P Batlle Gómez, Eduard
P Bigas Salvans, Anna
Publ. Q1 D1
Institución / Centro
Provincia
10
7
3
Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla
Sevilla
29
20
13
Consorci Mar Parc Salut de Barcelona
Barcelona
8
6
3
Fundación para la Investigación Biomédica de Córdoba (FIBICO)
Córdoba
7
7
3
Fundación Privada Instituto de Investigación Oncológica Valle de Hébron-VHIO
Barcelona
4
2
1
Fundación privada Instituto de Recerca Biomédica (IRB- Barcelona)
Barcelona
12
6
4
Consorci Mar Parc Salut de Barcelona
Barcelona